RecruitingNot ApplicableNCT06273800
Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients
Sponsor
The Netherlands Cancer Institute
Enrollment
100 participants
Start Date
Oct 14, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study is a prospective, multicenter study in which a serum sample will be collected at the day of starting neo adjuvant treatment in breast cancer patients
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 59 Years
Plain Language Summary
Simplified for easier understanding
This study is investigating whether the phase of a woman's menstrual cycle at the time she receives chemotherapy affects how sensitive her tumor cells are to the treatment. The focus is on women with triple-negative breast cancer, which tends to be more aggressive.
**You may be eligible if...**
- You are a woman under 60 years old
- You have a new diagnosis of triple-negative breast cancer (stages I–III)
- You have a regular menstrual cycle and have not yet started any systemic treatment
- Your doctor has recommended neoadjuvant chemotherapy (chemotherapy before surgery)
**You may NOT be eligible if...**
- You are currently using hormonal contraception or have recently stopped
- You have started any previous systemic cancer treatment
- You are menopausal or have an irregular cycle
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREBlood sample
Collection of serum sample at the day of start of neo adjuvant treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06273800
Related Trials
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT058799261238 locations
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
NCT072146624 locations
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693226 locations
Shoulder Denervation for Post Mastectomy Irradiation Shoulder Pain
NCT070955691 location
Genomic Services Research Program
NCT025959571 location